Recent

% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

  • misskellyfitz misskellyfitz Mar 10, 2013 5:08 PM Flag

    Venofer the Support Drug for Gets the Blame For Sure,the FDA need Look No farther than the Label

    Venofer,

    1st line of Venofer safety disclaimer:

    IMPORTANT SAFETY INFORMATION
    Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Venofer® (iron sucrose injection, USP). Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. If hypersensitivity reactions or signs of intolerance occur during administration, stop Venofer® immediately. Monitor patients for signs and symptoms of hypersensitivity during and after Venofer® administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Venofer® when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.

    If hypersensitivity reactions or signs of intolerance occur during administration, stop Venofer® immediately.

    administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Venofer® when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.

    Venofer® may cause clinically significant hypotension. Monitor for signs and symptoms of hypotension following each administration of Venofer®. Hypotension following administration of Venofer® may be related to rate of administration and total dose delivered.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Venofer,

      1st line of Venofer safety disclaimer:

      IMPORTANT SAFETY INFORMATION
      Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Venofer® (iron sucrose injection, USP). Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. If hypersensitivity reactions or signs of intolerance occur during administration, stop Venofer® immediately. Monitor patients for signs and symptoms of hypersensitivity during and after Venofer® administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Venofer® when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.

      If hypersensitivity reactions or signs of intolerance occur during administration, stop Venofer® immediately.

      administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Venofer® when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.

      Venofer® may cause clinically significant hypotension. Monitor for signs and symptoms of hypotension following each administration of Venofer®. Hypotension following administration of Venofer® may be related to rate of administration and total dose delivered.

    • thegreymatter shorted at $2.50 because he Didn't Read Venofer Label

      OOPS

 
AFFY
0.113+0.0200(+1.67%)May 26 3:33 PMEDT